Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2

José L. Casado,Pilar Vizcarra,Johannes Haemmerle,Héctor Velasco,Adrián Martín-Hondarza,Mario J. Rodríguez-Domínguez,Tamara Velasco,Sara Martín,Beatriz Romero-Hernández,Marina Fernández-Escribano,Alejandro Vallejo,José L. Casado,Pilar Vizcarra,Johannes Haemmerle,Héctor Velasco,Adrián Martín-Hondarza,Mario J. Rodríguez-Domínguez,Tamara Velasco,Sara Martín,Beatriz Romero-Hernández,Marina Fernández-Escribano,Alejandro Vallejo

DOI: https://doi.org/10.1016/j.jvacx.2022.100165

2022-08-01

Vaccine: X

Abstract:Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4+ and CD8+ T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4+ T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination.